Novo Nordisk confirms Capital Markets Day falls on September 21, separate from September 15 staff event

Novo Nordisk's next set of long-term business goals will be unveiled at its Capital Markets Day on September 21, 2026, according to the company's own disclosures ^[1]. A separate, employee-only town hall held on September 15 was billed internally as an update on the company's "next chapter" and took place ahead of the investor event ^[2].

In its annual financial report published February 3, 2026, Novo Nordisk said it "expects to introduce new Strategic Aspirations as part of Capital Markets Day on 21 September 2026," and that until then it would keep reporting progress across existing business measures ^[1]. That language matters because the company's previous Strategic Aspirations, introduced in 2019, were set to conclude in 2025 ^[1].

Bloomberg reported that Novo invited employees to a town hall on September 15 to "share an exciting update about our company's next chapter," citing an invitation it had seen ^[2]. A spokesperson for the Danish drugmaker confirmed an internal event was scheduled then, ahead of the capital markets day on September 21 ^[2]. What was said at the staff meeting has not been disclosed, and the contents of the new strategy — including any financial targets or fresh commitments in the obesity market — had not been made public as of mid-September.

What the company has already said

The backdrop is a tougher year. Novo Nordisk reported 2025 sales of DKK 309.1 billion, up 6% in Danish kroner and 10% at constant exchange rates, with operating profit of DKK 127.7 billion, down 1% as reported and up 6% at constant rates after roughly DKK 8 billion in costs tied to a company-wide transformation ^[1]. Obesity care sales rose 31% at constant rates to DKK 82.3 billion, up from DKK 6 billion in 2019 ^[1]. The company's diabetes value market share fell 3.6 percentage points to 30.1% ^[1].

For 2026, Novo Nordisk guided to adjusted sales growth of -5% to -13% at constant exchange rates, excluding revenue from a USD 4.2 billion reversal of rebate provisions related to the US 340B Drug Pricing Program ^[1]. Adjusted operating profit growth was guided to the same -5% to -13% range at constant rates ^[1]. The company attributed the outlook to lower realized prices, including effects tied to the "Most Favoured Nations" agreement in the US, the semaglutide patent expiry in certain international markets, and competition ^[1].

On products, the FDA approved once-daily oral semaglutide 25 mg for obesity on December 22 under the brand name Wegovy pill — described by the company as the first oral GLP-1 in obesity ^[1]. It launched January 5, 2026, and as of January 23, total weekly prescriptions were around 50,000, driven mainly by the 1.5 mg starter dose in the self-pay channel ^[1]. Novo Nordisk has also submitted semaglutide 7.2 mg and CagriSema to the FDA ^[1].

Why it matters for patients

Strategy days set the priorities that shape which medicines a company pushes hardest, how it prices them and where it invests. Novo Nordisk's 2026 guidance already points to falling realized prices in the US and more competition ^[1], and the early Wegovy pill uptake has been concentrated in the cash-pay channel rather than through insurance ^[1]. Whether the new Strategic Aspirations include specific commitments on access, pricing or the obesity pipeline is not yet known.

Nothing announced on September 15 or September 21 changes a drug's approved labeling or an insurer's coverage rules on its own. Coverage decisions are made by health plans and employers, and regulatory decisions on pending products rest with the FDA.

What happens next

The Capital Markets Day is scheduled for September 21, 2026, when the company says it will introduce the new Strategic Aspirations ^[1]. FDA decisions on semaglutide 7.2 mg and CagriSema are pending; specific action dates have not been disclosed ^[1]. Chief executive Mike Doustdar said the company looks forward to 2026 regulatory decisions for next-generation treatments including CagriSema in obesity ^[1].